GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Harmony Biosciences
Harmony Biosciences is a pharmaceutical company whose commercial success is built on a single drug, WAKIX, for the treatment of narcolepsy. Its stock price reflects the growing sales of this drug and the company's efforts to expand its use and develop new drugs.
Share prices of companies in the market segment - Neuro
Harmony Biosciences is a pharmaceutical company focused on one segment—the treatment of rare neurological diseases. Its main product is designed to treat narcolepsy. We classify it in the Neuro sector, and the chart below shows the dynamics of the entire neurological drug segment.
Broad Market Index - GURU.Markets
Harmony Biosciences is a pharmaceutical company focused on developing treatments for rare neurological diseases, particularly narcolepsy. It is a component of the GURU.Markets index. The chart below represents the market. See how Harmony shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
HRMY - Daily change in the company's share price Harmony Biosciences
The daily price change of Harmony Biosciences, a pharmaceutical company, reflects the volatility associated with its key drug. change_co measures the reaction to sales volumes and competitive news. This metric is important for analyzing companies with the same product on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Harmony Biosciences Holdings, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to HRMY, whose success hinges on a single sleep disorder drug, helps to understand its high concentration risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Harmony Biosciences is a pharmaceutical company specializing in drugs for the treatment of rare neurological diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Harmony's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Harmony Biosciences
Harmony Biosciences is a biopharmaceutical company specializing in the treatment of diseases of the central nervous system. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform.
Annual dynamics of market capitalization of the market segment - Neuro
Harmony Biosciences Holdings, Inc. is a commercial pharmaceutical company focused on treating rare neurological diseases. Its success is based on its key drug for narcolepsy. The chart below shows how its niche strategy and efforts to expand the reach of its drug are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Harmony Biosciences is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Harmony Biosciences
Harmony Biosciences' market capitalization depends on the success of its single drug. The monthly fluctuations on the chart reflect sales data for its narcolepsy drug, as well as news about clinical trials aimed at expanding its use to treat other sleep disorders.
Monthly dynamics of market capitalization of the market segment - Neuro
This chart reflects the dynamics of the biotech sector. For Harmony, with its focus on treating rare neurological diseases, it's the backdrop. Its movements demonstrate how the commercial success of its lead drug allows it to grow steadily and invest in new developments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. The company's success depends on sales of its key drug. This creates a stock price performance that is loosely tied to the market and heavily dependent on quarterly sales reports and news in its narrow therapeutic area.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Harmony Biosciences
Harmony Biosciences Holdings is a pharmaceutical company focused on treating rare neurological diseases. Its weekly stock price is driven by sales of its flagship drug for narcolepsy and progress in expanding its use to other indications.
Weekly dynamics of market capitalization of the market segment - Neuro
Harmony, as a pharmaceutical company with a single core product, can move differently than diversified giants. The successful launch and sales growth of its drug is a unique driver. The chart allows for comparison with the broader pharmaceutical sector and shows how the market views a growth story focused on a single drug.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Harmony Biosciences is a pharmaceutical company with a successful drug for treating narcolepsy. Dependence on a single product creates risks, but also ensures growth. The chart shows how its shares have a life of their own, ignoring short-term market noise.
Market capitalization of the company, segment and market as a whole
HRMY - Market capitalization of the company Harmony Biosciences
Harmony Biosciences' market capitalization chart is a success story of a "single-product" company. Its robust growth is based on its narcolepsy drug WAKIX. Its share price dynamics reflect investors' perceptions of the drug's commercial success and the company's ability to expand its use and develop other products.
HRMY - Share of the company's market capitalization Harmony Biosciences within the market segment - Neuro
Harmony Biosciences holds its market share through its narcolepsy drug. Its market capitalization is based on the success of this product and its efforts to expand its use for other sleep disorders.
Market capitalization of the market segment - Neuro
Below is a chart of the neuroscience pharmaceutical sector market capitalization. Harmony Biosciences is a unique company whose success is based on a single drug for the treatment of narcolepsy. Its market history exemplifies how even a single successful product in a niche area can create a multibillion-dollar, highly profitable company.
Market capitalization of all companies included in a broad market index - GURU.Markets
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases, particularly narcolepsy. Its market capitalization reflects its leadership in this niche. The chart below shows the economic weight of companies solving orphan diseases.
Book value capitalization of the company, segment and market as a whole
HRMY - Book value capitalization of the company Harmony Biosciences
Harmony Biosciences' book value is derived from its intellectual property rights to its narcolepsy drug WAKIX and the capital generated from its sales. The chart depicts the commercialization of a single product, with all revenues being channeled into its promotion and the search for new indications, strengthening the company's financial foundation.
HRMY - Share of the company's book capitalization Harmony Biosciences within the market segment - Neuro
Harmony Biosciences specializes in treating rare neurological diseases. The chart shows its share of actual R&D and commercial assets. These include its offices and sales support infrastructure, which ensures patient access to its drugs.
Market segment balance sheet capitalization - Neuro
Harmony Biosciences is a commercial pharmaceutical company, making it moderately capital-intensive. In addition to R&D, it has a commercial infrastructure for its narcolepsy drug. Compared to the biotech sector, it is more "heavy" than purely R&D companies, as it incurs sales and marketing costs.
Book value of all companies included in the broad market index - GURU.Markets
Harmony Biosciences' assets are not a vast portfolio, but rather a focused effort on commercializing a drug for the treatment of narcolepsy and related disorders. The company's balance sheet reflects the value of the rights to this vital product. The chart shows the capital behind the company restoring normal lives to people.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Harmony Biosciences
Harmony Biosciences is a pharmaceutical company with a single key product for the treatment of a rare neurological disorder. Its market capitalization is based on sales of this drug and its potential for treating other diseases. This is not a valuation of assets, but rather the successful commercialization of a single blockbuster.
Market to book capitalization ratio in a market segment - Neuro
Harmony Biosciences is a pharmaceutical company focused on sleep disorders. Its value depends almost entirely on the success of one key product. This chart shows how the market values this drug's sales potential and its patent protection.
Market to book capitalization ratio for the market as a whole
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. Its value depends almost entirely on the success of its key drug. The chart shows how the market values a pharmaceutical company with a concentrated portfolio, where value is created by intellectual property rather than manufacturing plants.
Debts of the company, segment and market as a whole
HRMY - Company debts Harmony Biosciences
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. Its commercial success depends on effective marketing and expanding patient access to its drugs. Debt instruments can be used to finance these commercial efforts and research into new indications for its drugs.
Market segment debts - Neuro
Harmony Biosciences is a pharmaceutical company specializing in the treatment of rare neurological diseases. Its lead product is designed to treat narcolepsy. This chart shows how the company manages its balance sheet following the successful commercialization of its key drug, using cash flow for research and potential portfolio expansion.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Harmony Biosciences
Harmony Biosciences is a pharmaceutical company focused on drugs for rare neurological diseases. This chart demonstrates its successful commercialization. Strong cash flow from its core product allows the company to maintain low debt and fund clinical trials to expand its use internally.
Market segment debt to market segment book capitalization - Neuro
Harmony Biosciences is a pharmaceutical company focused on treating diseases of the central nervous system. The chart reflects the debt burden in the neurosciences sector. It helps understand how the company's financial strategy for commercializing its key products and funding new research aligns with industry norms.
Debt to book value of all companies in the market
Harmony Biosciences, a pharmaceutical company, enjoys stable demand for its products. The chart reflects the overall debt burden for the entire economy. It helps understand the extent to which the healthcare sector, particularly in niches with unmet demand, can maintain a financial policy unaffected by overall market fluctuations.
P/E of the company, segment and market as a whole
P/E - Harmony Biosciences
For Harmony Biosciences, a pharmaceutical company focused on treating rare neurological diseases, this chart is an assessment of its monopoly position. The company's lead drug is designed to treat narcolepsy. The price-to-earnings ratio shows how investors assess its commercial potential and competitive advantage.
P/E of the market segment - Neuro
This chart reflects the average valuation for the biopharmaceutical sector—the benchmark for Harmony. Comparing this company's valuation with the industry average, which is based on a single key drug, helps understand how investors value its near-monopoly position in its niche and its expected stable cash flow.
P/E of the market as a whole
Harmony Biosciences is a pharmaceutical company focused on drugs for rare neurological diseases. Its main product is designed to treat narcolepsy. This chart of overall healthcare sentiment helps understand how investors value companies dependent on a single product. Do they value dominance in a niche or fear the loss of exclusivity?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Harmony Biosciences
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. Its primary revenue comes from a drug for the treatment of narcolepsy. The company's future depends on the growth of this drug's sales and the expansion of its use. This chart reflects analysts' forecasts for the market potential of its key product.
%20P%2FE%20Harmony%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Harmony-Biosciences&v=1772660418520 "Chart of the company's future (projected) P/E Harmony Biosciences")
Future (projected) P/E of the market segment - Neuro
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. Its valuation relative to other biotechs reflects investor sentiment on its lead drug, a treatment for narcolepsy. This reflects investors' confidence in its continued sales growth and potential for use in other conditions.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772660418530 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Harmony Biosciences is a pharmaceutical company whose primary product is designed to treat a rare neurological disorder, narcolepsy. The company's success depends on expanding the use of its drug. This chart shows the overall market sentiment that influences the valuation of niche pharmaceutical companies. It reflects how investors value stable cash flows from unique products.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772660418532 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Harmony Biosciences
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. Its financial results, presented in this chart, are primarily driven by sales of its only commercial product for the treatment of narcolepsy. Successful marketing and indication expansion are key to its growth.
Profit of companies in the market segment - Neuro
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases, particularly narcolepsy. This chart reflects the financial health of the neuroscience segment of the biotech industry. It demonstrates the commercial success of drugs for orphan (rare) diseases with high unmet demand.
Overall market profit
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. Its main product is designed for patients with narcolepsy. Demand for this treatment is driven by medical needs and is independent of economic conditions. This makes HRMY's business resilient to cycles, as illustrated in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Harmony Biosciences
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases, particularly narcolepsy. Its future profitability depends almost entirely on sales of its only commercial product. This chart shows analysts' estimates of this drug's growth potential and ability to maintain market share.
%20profit%20of%20the%20company%20Harmony%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Harmony-Biosciences&v=1772660418618 "Graph of future (projected) profit of the company Harmony Biosciences")
Future (predicted) profit of companies in the market segment - Neuro
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. Its sole commercial product is for narcolepsy and related disorders. This chart shows forecasts for the neuroscience segment. It helps assess how the presence of one successful drug and its potential expansion impact the company's growth.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772660418668 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Harmony Biosciences is a pharmaceutical company specializing in the treatment of rare neurological diseases. This projected profit curve is impacting the investment climate in the biotech sector. Market optimism and economic growth are facilitating capital raising for the commercialization and further research of drugs for patients with serious diseases.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772660418692 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Harmony Biosciences
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. This chart shows how investors value its revenue, which is primarily generated by a single drug. It reflects both its success and the risks associated with reliance on a single product.
P/S market segment - Neuro
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. This chart shows the average valuation in the neuroscience sector. It reflects how investors view the success of its lead drug for narcolepsy and the potential for expanding its use to other sleep-wake disorders.
P/S of the market as a whole
Harmony Biosciences Holdings is a pharmaceutical company focused on treating rare neurological diseases. Its lead product is designed to treat narcolepsy. The company's revenue depends on the success of this single drug. This chart helps assess how the market values a company with a concentrated, yet patent-protected, product portfolio.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Harmony Biosciences
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. Its future revenue depends on sales of its only approved drug for narcolepsy. The chart shows how investors view the drug's potential and the company's ability to expand its use.
%20P%2FS%20Harmony%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Harmony-Biosciences&v=1772660418993 "The graph of the company's future (projected) P/S Harmony Biosciences")
Future (projected) P/S of the market segment - Neuro
Harmony Biosciences is a pharmaceutical company focused on developing and commercializing treatments for rare neurological diseases. Its lead product is designed to treat narcolepsy. This chart shows how the market perceives the sales potential of its niche drugs compared to other companies working in the neuroscience field.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772660419035 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
This chart reflects expectations for the biotech market. For Harmony Biosciences, a company focused on treating rare neurological diseases such as narcolepsy, this indicates stable demand. Demand for its drugs is unaffected by economic cycles, attracting investors seeking predictable growth in the healthcare sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772660419064 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Harmony Biosciences
Harmony Biosciences is a pharmaceutical company focused on developing and commercializing treatments for rare neurological diseases. Its lead product is a treatment for narcolepsy. This chart shows sales revenue for this drug. Sales growth reflects successful patient reach and increased awareness of the disease.
Sales of companies in the market segment - Neuro
Harmony Biosciences is a pharmaceutical company specializing in the treatment of rare neurological diseases. This chart shows growth in the neuroscience sector. Its lead product is designed to treat narcolepsy. Harmony's success demonstrates how focusing on a specific but unmet medical need can lead to a successful business.
Overall market sales
Harmony Biosciences Holdings is a pharmaceutical company specializing in the treatment of central nervous system disorders, particularly narcolepsy. Its revenue depends on sales of its key drug. The overall economic situation, reflected in this chart, affects the availability of insurance coverage and patient affordability.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Harmony Biosciences
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. Its lead product is designed for patients with narcolepsy. The company's growth depends on the expansion of this drug. This chart shows analyst expectations for the commercial success of the company's key product and the potential for future developments.
%20sales%20of%20the%20company%20Harmony%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Harmony-Biosciences&v=1772660419197 "Schedule of future (projected) sales of the company Harmony Biosciences")
Future (projected) sales of companies in the market segment - Neuro
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases, particularly narcolepsy. This forecast provides insight into the future of the neurological pharmaceutical segment, reflecting the potential for drugs aimed at improving the quality of life of patients with chronic central nervous system disorders.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772660419201 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Harmony Biosciences is a pharmaceutical company focused on developing and commercializing treatments for rare neurological diseases. Its primary product is a treatment for narcolepsy. This graph, reflecting the overall economic situation, affects the solvency of the healthcare system and the willingness of insurers to cover the cost of specialized drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772660419202 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Harmony Biosciences
Harmony Biosciences is a pharmaceutical company whose success is built on a single drug for the treatment of narcolepsy. This chart illustrates how profitable focusing on a niche condition can be. The company's profitability depends almost entirely on sales of this single product, requiring constant marketing efforts and the search for new indications.
Market segment marginality - Neuro
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. Its primary product is designed for people with narcolepsy. Profitability depends on the success of this drug and the development of new ones. This chart shows the operating efficiency of its commercial model compared to other companies working in the neuroscience field.
Market marginality as a whole
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. This overall market profitability chart is not a defining characteristic for the company. Its success and profitability depend on its key drug and its ability to expand its use, as well as on intellectual property protection, rather than on the overall economic situation.
Employees in the company, segment and market as a whole
Number of employees in the company Harmony Biosciences
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. The graph shows the team commercializing its lead product for narcolepsy. The growth in headcount, particularly in sales, reflects successful market penetration and exploration of new indications.
Share of the company's employees Harmony Biosciences within the market segment - Neuro
Harmony Biosciences focuses on treating rare neurological diseases, with its key product being a drug for narcolepsy. This chart shows the percentage of neurologists, researchers, and sales professionals the company attracts in this narrow therapeutic area. It reflects its deep expertise and talent concentration on specific CNS diseases.
Number of employees in the market segment - Neuro
Harmony Biosciences Holdings, Inc. is a pharmaceutical company focused on developing and commercializing treatments for patients with rare neurological diseases. Its lead product is designed to treat narcolepsy. This chart reflects the neurological pharmaceutical sector, demonstrating how a focus on orphan diseases can lead to the creation of a successful and growing business.
Number of employees in the market as a whole
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. Their primary product is designed for people suffering from narcolepsy. It's a highly specialized business whose success depends on scientific development and drug efficacy, not on general economic cycles. They create jobs for highly qualified specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Harmony Biosciences (HRMY)
Harmony Biosciences is a pharmaceutical company focused on treating diseases of the central nervous system. This chart shows how the market values commercial success. Its high market capitalization per employee reflects strong sales of its key drug and the potential for expanding its use, creating significant value.
%20of%20the%20company%20Harmony%20Biosciences%20(HRMY)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Harmony-Biosciences-HRMY&v=1772660419666 "Chart of market capitalization per employee (in thousands of dollars) of the company Harmony Biosciences (HRMY)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Harmony Biosciences (HRMY) is a pharmaceutical company focused on treating rare neurological diseases. Their key product is WAKIX for the treatment of narcolepsy. This chart shows the industry average cost per employee. It helps assess how the market values their commercial success with WAKIX and their R&D portfolio per employee.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772660419735 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Harmony Biosciences is a pharmaceutical company specializing in the treatment of central nervous system disorders. This chart shows the average market value of each employee's contribution. It illustrates how the market values a company with a successful commercialized product and potential.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772660419787 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Harmony Biosciences (HRMY)
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. They have an approved product. This graph shows how effectively their small but focused team (R&D and sales) can commercialize their product, generating high net profit per employee.
%20Chart%20Harmony%20Biosciences%20(HRMY)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Harmony-Biosciences-HRMY&v=1772660420023 "Company Profit Per Employee (in thousands of dollars) Chart Harmony Biosciences (HRMY)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Harmony Bio (HRMY) is a "one-hit biotech" (WAKIX - narcolepsy treatment). This chart shows the benchmark for "Neuro" (Pharma). The average profit per employee in this sector (biotech) is astronomical. It's a "blockbuster business." A single successful patent for a drug for a rare disease (with a very high price tag) can generate billions.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772660420118 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Harmony Biosciences (HRMY) is a biopharmaceutical company whose primary (and only) product is WAKIX, a treatment for narcolepsy. It's a single-product company. This chart shows how profitable this drug is. The high profit per employee reflects the small R&D and marketing team managing a highly successful and profitable niche drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772660420173 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Harmony Biosciences (HRMY)
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. This chart demonstrates the effectiveness of a single-product strategy. It illustrates how the commercial success of a single key drug can generate significant revenue for a company with a relatively small team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Harmony-Biosciences-HRMY&v=1772660420391 "Sales chart per company employee Harmony Biosciences (HRMY)")
Sales per employee in the market segment - Neuro
Harmony Biosciences is a commercial pharmaceutical company specializing in the treatment of rare neurological diseases, particularly narcolepsy. This chart shows the average revenue per employee in this segment. It helps us understand how effectively Harmony's small team monetizes its drugs in this niche compared to other pharmaceutical companies.
Sales per employee for the market as a whole
Harmony Biosciences is a pharmaceutical company focused on treating rare neurological diseases. They have one commercial product for the treatment of narcolepsy. This chart shows how productive their small, highly specialized team (R&D and sales) is in generating revenue from sales of their single, yet very niche, drug.
Short shares by company, segment and market as a whole
Shares shorted by company Harmony Biosciences (HRMY)
Harmony Biosciences is a pharmaceutical company whose success depends almost entirely on a single drug (Wakix) for the treatment of narcolepsy. This mono-dependency is extremely risky. This chart shows the percentage of bears betting on the emergence of a strong competitor or that Wakix sales have peaked and will begin to decline.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Harmony-Biosciences-HRMY&v=1772660420654 "Short Shares Chart for the Company Harmony Biosciences (HRMY)")
Shares shorted by market segment - Neuro
Harmony Biosciences is a pharmaceutical company whose main product, WAKIX (pitazolisant), is designed to treat excessive daytime sleepiness in patients with narcolepsy. This chart shows the overall short position in the neuroscience-focused biotech sector. Its rise signals investor skepticism about the commercial potential of niche drugs or the risk of competitors entering the market.
Shares shorted by the overall market
Harmony (HRMY) is a pharmaceutical company whose revenue depends on a single drug (Wakix). This indicator (`Short_All`) is a proxy for market fear. When it rises, investors panic and shed risk. This pessimism weighs on stocks like HRMY due to the fear of concentration (dependence on a single product) in volatile times.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Harmony Biosciences (HRMY)
Harmony Biosciences (HRMY) focuses on drugs for rare neurological diseases (narcolepsy). Success depends on the key drug. A chart above 70 may reflect strong selling or positive news. Oversold levels (<30) are often associated with concerns about competition, patent disputes, or R&D setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Harmony-Biosciences-HRMY&v=1772660420769 "RSI 14 indicator chart for the company's stock Harmony Biosciences (HRMY)")
RSI 14 Market Segment - Neuro
Harmony Biosciences (HRMY) is a biotech company whose sole product (Wakix) is a drug for the treatment of narcolepsy. The RSI_14_Seg for "Neuro" (biotech) shows the overall sentiment. The chart helps us understand: is HRMY's volatility a reflection of its commercial success, or is the entire biotech sector overheated (or oversold)?
RSI 14 for the overall market
Harmony Biosciences (HRMY) is a pharmaceutical company. This chart reflects the mood in the sector. During periods of euphoria, investors are willing to fund R&D. During moments of panic, they look for companies with existing sales. HRMY, with both, may be more stable than pure biotech companies.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HRMY (Harmony Biosciences)
Harmony Biosciences (HRMY) is a pharmaceutical company whose key product (WAKIX) is designed to treat narcolepsy. This chart shows the average 12-month analyst forecast, reflecting their expectations for sales growth for this drug and its potential approval for the treatment of other sleep disorders.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HRMY-Harmony-Biosciences&v=1772660420919 "A chart showing analyst consensus forecasts for the expected stock price. HRMY (Harmony Biosciences)")
The difference between the consensus estimate and the actual stock price HRMY (Harmony Biosciences)
Harmony Biosciences is a single-product company. Its success is WAKIX, a drug for the treatment of narcolepsy (excessive sleepiness). This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in WAKIX's growth potential (indication expansion) and its R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HRMY-Harmony-Biosciences&v=1772660420963 "A chart showing the difference between the consensus forecast and the actual stock price. HRMY (Harmony Biosciences)")
Analyst consensus forecast for stock prices by market segment - Neuro
Harmony Biosciences is a pharmaceutical company specializing in rare neurological diseases. Its lead product, Wakix, treats narcolepsy. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe Wakix has the potential to be used for other sleep disorders.
Analysts' consensus forecast for the overall market share price
Harmony Biosciences is a biopharmaceutical company focused on rare neurological diseases. Their main product is a drug for the treatment of narcolepsy. This chart shows overall market sentiment. For Harmony, whose success depends on sales of one key drug, overall optimism is important, but investors are more interested in prescription volume and patent protection.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Harmony Biosciences
Harmony Biosciences is not a diversified pharmaceutical company, but a single-product company. Their business is WAKIX, a unique drug for the treatment of narcolepsy (excessive daytime sleepiness). This chart is an assessment of their single-product. It measures the growth rate of patients taking WAKIX and their ability to protect their drug from competition.
AKIMA Market Segment Index - Neuro
Harmony (HRMY) is a single-product biotech (for now); the company dominates the narcolepsy treatment market (competing with Jazz) with its unique drug, WAKIX. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this niche monopoly (WAKIX) differentiate HRMY from the average pharma company?
The AKIM Index for the overall market
Harmony Biosciences is a pharmaceutical company specializing in rare neurological diseases. Its key product is Wakix (narcolepsy). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this commercially successful biopharma stacks up against the broader economic trends affecting the healthcare sector.
